Dr. Sarah Jarvis Richford Gate Medical Practice London UK, comments on the importance of tolerabilty in CVD treatment

The results of the TRANSCEND® trial demonstrate that telmisartan 80mg reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.048), referring to the same endpoint as that defined as the primary endpoint of the landmark HOPE trial published in 2000.1,2 Therapy with telmisartan was well tolerated and showed a trend towards a lower rate of discontinuation.1

The new data on 5,926 patients from 40 countries were presented today at the annual congress of the European Society of Cardiology (ESC) in Munich, Germany. TRANSCEND®* is the first landmark trial to test and prove the cardiovascular protective effects of an angiotensin II receptor blocker (ARB) – Boehringer Ingelheim's telmisartan – versus placebo, on top of standard therapy (including anti-hypertensives, anti-platelet therapy and statins), in high-risk individuals who cannot tolerate an angiotensin converting enzyme (ACE)-inhibitor.

To view Multimedia News Release, go to http://www.prnewswire.com/mnr/boehringeringelheim/34677/